<DOC>
	<DOCNO>NCT00634452</DOCNO>
	<brief_summary>To establish safety tolerability profile MDX-1401 patient relapse refractory Hodgkin 's Lymphoma ( HL ) .</brief_summary>
	<brief_title>Phase 1 Study MDX-1401 Patients With CD30-positive Refractory/Relapsed Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Diagnosis CD30positive HL immunohistochemistry flow cytometry Must fail relapse follow second line chemotherapy radiation failed/relapsed follow autologous stem cell transplant Bimeasurable disease ECOG Performance Status 0 2 Meet screening laboratory value Previous treatment antiCD30 antibody History allogeneic transplant Any tumor lesion great equal 10 cm diameter Any active chronic significant infection Underlying medical condition make administration MDX 1401 hazardous Concomitant corticosteroid , chemotherapy , investigational agent , antiHL biologics , radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hodgkin 's</keyword>
	<keyword>Cancer</keyword>
	<keyword>bi-measurable disease</keyword>
	<keyword>Lymphoma</keyword>
</DOC>